Werblin T P, Patel A S, Barraquer J I
University of Virginia, Charlottesville.
Refract Corneal Surg. 1992 Jan-Feb;8(1):23-6.
Previous nonhuman primate experimentation has demonstrated the successful use of Permalens hydrogel intracorneal lens implants for the correction of hyperopic and myopic refractive errors. This article documents the first human experience with myopic Permalens hydrogel intracorneal lens implants.
In this article, we report an 18-month follow up on five patients implanted with minus power hydrogel intracorneal lenses. All surgery and follow-up examinations were performed in Bogota, Columbia. The mean preoperative spherical refraction was -14.00 +/- 5.00 diopters (range, -9.5 to -19.00 D).
Corrections of up to 13.00 D were achieved. Corrections deviated from the predicted correction by a mean of -5.00 +/- 2.10 D (range, -2.80 to -8.00 D). No significant surgical or postoperative complications were noted. Visual recovery was rapid, usually achieving maximum acuity within 1 month.
Successful myopic refractive changes were accomplished in all five human subjects. The major problem with the study to date has been a significant undercorrection of the preoperative refraction. We anticipate that further empirically derived relationships between hydrogel lens power and refractive change will allow a more accurate prediction of refractive result. Also, the ability to surgically interchange myopic hydrogel inlays should allow correction of any residual refractive errors.
先前的非人灵长类动物实验已证明，Permalens水凝胶角膜内透镜植入物可成功用于矫正远视和近视屈光不正。本文记录了首例使用Permalens水凝胶角膜内透镜植入物矫正近视的人体试验情况。
在本文中，我们报告了对5例植入负屈光度水凝胶角膜内透镜患者的18个月随访情况。所有手术及随访检查均在哥伦比亚波哥大进行。术前平均球镜度为-14.00±5.00屈光度（范围为-9.5至-19.00 D）。
实现了高达13.00 D的矫正。实际矫正值与预期矫正值平均偏差为-5.00±2.10 D（范围为-2.80至-8.00 D）。未发现明显的手术或术后并发症。视力恢复迅速，通常在1个月内达到最佳视力。
所有5例受试者均成功实现了近视屈光改变。迄今为止，该研究的主要问题是术前屈光不正矫正不足。我们预计，通过进一步从经验中得出水凝胶透镜屈光度与屈光改变之间的关系，将能更准确地预测屈光结果。此外，通过手术更换近视水凝胶镶嵌物的能力应能矫正任何残余屈光不正。
